An exception to that is Fresolimumab (NCT03064074; clinicaltrials.gov) (neutralizing anti-TGF-β antibody) which specifically targets TGF-β signaling in OI with CRTAP and COL1A2 defects (Grafe et al. 2014). Here, COL1A2 is linked to osteogenesis imperfecta.